Please login to the form below

Not currently logged in
Email:
Password:

Chase Pharmaceuticals appoints former Allergan president

Douglas Ingram joins as chief executive officer
Douglas Ingram

Washington-based Chase Pharmaceuticals has appointed Douglas Ingram as its new chief executive officer to replace John Siebert, who will continue working with the company in an advisory capacity.

He brings to the role nearly 20 years of experience in biotech, pharmaceutical and medical devices leadership.

Prior to serving as president of Allergan, Ingram directed the company's operations in Europe, the Middle East and Africa and was responsible for various aspects of its global organisation including regulatory affairs and external communications.

Ingram said: “I am privileged to lead Chase Pharmaceuticals as we execute an elegant approach to the development of new Alzheimer's treatments.

“Our goal is to build a strong CNS biopharmaceutical company to improve the lives of the millions of patients and their families burdened by this devastating disease. We have an important mission and I am excited to play a leadership role in this journey.”

As CEO, Ingram will focus on the direction of Chase Pharmaceuticals' development and commercialisation of improved treatments for neurodegenerative disorders, in particular its current work on symptomatic treatment of Alzheimer's disease.

Greg Parekh, chairman of Chase Pharmaceuticals, said: “Doug has a proven track record of disruptive approaches, building strong teams and delivering above-market performance … I am confident that Doug will successfully develop Chase to its fullest potential.”

15th December 2015

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics